Alight Inc (ALIT) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Alight Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Alight Inc's ROI in the second quarter of 2026?
Alight Inc had a negative return on investment (ROI) of -51.89%, due to the net loss of $-2 billion, during the twelve months ending in the second quarter of 2026.
Within the Services sector 23 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2217 to 3731.
Alight Responds to Starboard Value s Director Nominations, Ensuring Transparent Investor Relations LINCOLNSHIRE, Ill. - Alight, Inc. (NYSE: ALIT), a leading cloud-based human capital and technology services provider, has confirmed the receipt of director nominations from Starboard Value for election to the Alight Board of Directors at the 2024 Annual Meeting of Stockholders. In response, Alight issued a statement emphasizing the company s commitment to maintaining an active dialogue with all types of investors, including Starboard. The announcement comes as Alight continues to demonstrate its dedication to transparent investor relations and effective corporate governance. As a cloud-based human capital and technology services provider, Alight is well-suited to meeting the evolving needs of its customers in the digital age. With a strong track record of innovation, Alight has consistently delivered value to its stakeholders.
Alight Names Siobhan Nolan Mangini to Board of Directors: A Strategic Move Amidst Financial Challenges Lincolnshire, Illinois - Alight Inc. (NYSE: ALIT), a renowned cloud-based human capital technology and services provider, recently announced the appointment of Siobhan Nolan Mangini to its Board of Directors, effective January 1, 2024. With over two decades of experience in the healthcare industry, Ms. Nolan Mangini brings invaluable expertise to Alight, having served as President and CFO of NGM Biopharmaceuticals, Inc., a leading clinical-stage biopharmaceutical company specializing in immunotherapy and cardiometabolic therapies. The decision to bring Ms. Nolan Mangini onto the board comes during a challenging period for Alight Inc. The company s stock currently trades only 25.1% above its 52-week low, reflecting investor apprehension. Furthermore, in the 12 months ending in the third quarter of 2023, Alight Inc. recorded a cumulative net loss of $-258 million, resulting in a negative return on investment (ROI) of -2.79%. These financial figures place Alight Inc. behind 100 other companies in the Services sector in terms of ROI.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
